Furthermore, the link between FKBP51 expression levels and glioma severity, combined with the structural and functional distinctions between its isoforms (FKBP51 isoform 1 vs. FKBP51s/isoform 2), highlights its potential as a therapeutic target to improve treatment efficacy. The gene discussed is FKBP4; the disease is central nervous system cancer.